作者：
Zamek-Gliszczynski, Maciej J. [1]
;
Taub, Mitchell E. [2]
;
Chothe, Paresh P. [3]
;
Chu, Xiaoyan [4]
;
Giacomini, Kathleen M. [5]
;
Kim, Richard B. [6]
;
Ray, Adrian S. [7]
;
Stocker, Sophie L. [8]
;
Unadkat, Jashvant D. [9]
;
Wittwer, Matthias B. [10]
;
Xia, Cindy [11]
;
Yee, Sook-Wah [12]
;
Zhang, Lei [13]
;
Zhang, Yan
作者单位：
Vertex Pharmaceut, Drug Metab & Pharmacokinet, Boston, MA USA
[1]
Merck & Co Inc, Dept Pharmacokinet Pharmacodynam & Drug Metab, Kenilworth, NJ USA
[2]
GlaxoSmithKline, Quantitat Drug Disposit, King Of Prussia, PA USA
[3]
Nimbus Therapeut, Discovery Biol, Cambridge, MA USA
[4]
Boehringer Ingelheim GmbH & Co KG, Drug Metab & Pharmacokinet, Ridgefield, CT USA
[5]
F Hoffmann La Roche Basel, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Pharmaceut Sci
[6]
Incyte, Drug Metab Pharmacokinet & Clin Pharmacol, Wilmington, DE USA
[7]
Western Univ, Dept Med, Div Clin Pharmacol, London, ON, Canada
[8]
St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Sydney, NSW, Australia
[9]
Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
[10]
Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[11]
Takeda Pharmaceut Int, Drug Metab & Pharmacokinet, Cambridge, MA USA
[12]
US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[13]
发布时间
2019-05-22
换一批
换一批
